A Review of Treatment in Non-small-cell Lung Cancer

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Receive conference highlights, journal articles, and online medical education activities straight to your inbox.

Never Miss an Update

11 mins

Central Nervous System as a Sanctuary for Advanced Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer

Gabriel Lenz, Rafael Alvim Pereira, Milena Tumelero

Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, an estimated 2.48 million new cases of lung cancer were reported in 2022.4,5 Although lung cancer rates in the […]

touchREVIEWS in Oncology & Haematology. 2025;21(1):Online ahead of journal publication

Lung Cancer

< 1 min

A Review of Treatment in Non-small-cell Lung Cancer

Athanasios G Pallis

Published Online: Jun 21st 2012 European Respiratory Disease, 2011;7(1):27–31

Quick Links:

Select a Section…

1. Abstract

2. Article

3. Further Resources

4. Related Content

Abstract

Overview

Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. For patients with early-stage disease, surgery followed by adjuvant chemotherapy is the optimal treatment. For patients with locally advanced disease, the standard approach is chemoradiotherapy, since it offers a small but statistically significant prolongation in survival compared with the sequential approach. It should be noted, however, that this approach is associated with significant toxicity and it only applies to patients with good performance status. For patients with metastatic disease, chemotherapy represents the cornerstone of treatment and results in a median survival of approximately 10 months. Recently, the addition of bevacizumab or cetuximab to chemotherapy doublets and the use of gefitinib and erlotinib has improved the outcome in selected patients with advanced NSCLC. Hopefully, advances in understanding the molecular biology of cancer and mechanisms of tumourigenesis will facilitate the discovery and development of novel ‘targeted agents’ and will further improve outcomes for these patients.

Article

click here to read more

Further Resources

11 mins

Central Nervous System as a Sanctuary for Advanced Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer

Gabriel Lenz, Rafael Alvim Pereira, Milena Tumelero

touchREVIEWS in Oncology & Haematology. 2025;21(1):Online ahead of journal publication

Related Content in Lung Cancer

Foreword - touchREVIEWS in Oncology & Haematology, Volume 20, Issue 2, 2024

It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This issue highlights the remarkable progress and innovation shaping the fields of oncology and haematology, featuring articles that delve into both emerging therapies ...

Mesothelioma and Immunotherapies

Asrar A Alahmadi, Logan Roof, Claire Verschraegen

Highlights Immunotherapy, especially combinatory immunotherapy, has shown promise with prolonged survival for patients with advanced mesothelioma in the first-line setting (see the sections on ‘Systemic treatment and immunotherapy debut’ and ‘Randomized immunotherapy trials of mesothelioma’). Histology-based therapy is important to ...

touchREVIEWS in Oncology & Haematology. 2024;20(2):39–44

Foreword - touchREVIEWS in Oncology & Haematology, Volume 20, Issue 1, 2024

Axel S Merseburger

Welcome to the latest issue of touchREVIEWS in Oncology & Haematology. We are honoured to present a series of compelling articles that reflect cutting-edge developments and diverse perspectives in this ever-evolving field. This issue includes a series of editorials and ...

A New Frontier in the Treatment of Epidermal Growth Factor Receptor-mutated Non–Small-Cell Lung Cancer: Amivantamab-vmjw and Chemotherapy

Miguel García-Pardo, Pilar Garrido

Unmet clinical needs for patients with advanced epidermal growth factor receptor-mutated non–small-cell lung cancer Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have become the standard first-line therapy for patients with advanced non–small-cell lung cancer (NSCLC) harbouring ...

touchREVIEWS in Oncology & Haematology. 2024;20(1):5–8

Pafolacianine: A Diagnostic Agent to Identify Lung Cancer Lesions in Adults with Known or Suspected Lung Cancer

Linda Martin

Accurately detecting lung tumours and their margins is important for disease outcomes.1,2 However, detection is challenging due to the use of minimally invasive surgery and current localization techniques, such as computed tomography (CT)-guided and endobronchial interventions, which add significantly ...

touchREVIEWS in Oncology & Haematology. 2023;19(1):2-3 DOI: https://doi.org/10.17925/OHR.2023.19.1.2

Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer

Matthew Z Guo, Kristen A Marrone, Alexander Spira

Cancer treatment has expanded rapidly in recent years as advancements in the fields of tumour biology and molecular diagnostics have informed the development of targeted therapies, improving survival in patients with oncogene-addicted cancers with therapeutically relevant molecular lesions. Osimertinib has ...

touchREVIEWS in Oncology & Haematology. 2021;17(1):42-47 DOI: https://doi.org/10.17925/OHR.2021.17.1.42

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Patients with Non-small Cell Lung Cancer of Squamous Histology: Focus on Afatinib

Noemi Reguart, Roxana Reyes

The treatment of patients with non-small cell lung cancer (NSCLC) has seen significant advances in the past decade, with the availability of multiple targeted therapy agents for oncogenic-driven non-squamous NSCLC and the advent of immunotherapy that has completely revolutionized the ...

touchREVIEWS in Oncology & Haematology. 2021;17(1):36-41 DOI: https://doi.org/10.17925/OHR.2021.17.1.36

MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances

Rashmi Shah, Deepu Alex, Zhaolin Xu

Advanced non-small cell lung carcinoma (NSCLC) treatment paradigms have evolved during the past decade. Identification of tumor-specific molecular alteration in cancer driver genes has led to the development of targeted therapies.1–3 Most of the tumors harboring such alterations are sensitive ...

Oncology & Hematology Review (US). 100-10 DOI: https://doi.org/10.17925/OHR.2021.16.2.100

Radiation-induced Esophagitis in Lung Cancer—A Common Problem with Limited Therapeutic Options

Lawrence Berk

Radiation-induced esophagitis, caused by incidental damage to the mucosal lining of the esophagus during radiation therapy, is a common and clinically important toxicity in patients with lung cancer. Esophagitis generally develops 2–3 weeks after initiation of radiation therapy and presents as ...

Oncology & Hematology Review. 2020;16(2): 95-99 DOI: https://doi.org/10.17925/OHR.2021.16.2.95

Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy

Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli

Historically, chemotherapy represented the only available treatment for patients with advanced non-small-cell lung cancer (NSCLC) who did not show any target molecular driver, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or the receptor tyrosine kinase ROS1. ...

European Oncology & Haematology. 2020;16(1):39-43 DOI: https://doi.org/10.17925/EOH.2020.16.1.39

ALK Inhibitors in ALK-positive NSCLC with Central Nervous System Metastases

Mihaela Aldea, Benjamin Besse, Lizza EL Hendriks

At initial diagnosis of metastatic disease, central nervous system (CNS) metastases are present in 22–33% of patients with anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC). After crizotinib failure, the incidence can reach up to 70%, compared with 40% in ...

European Oncology & Haematology. 2020;16(1):18-21 DOI: https://doi.org/10.17925/EOH.2020.16.1.18

Targeting Tyrosine-protein Kinase Receptor (MET) Gene Alterations in Non-small Cell Lung Cancer – The Efficacy and Safety of Tepotinib + Gefitinib in the INSIGHT Study

Non-small cell lung cancer (NSCLC) remains a world-wide health issue, accounting for 85% of all lung cancers, of which there were an estimated 2.1 million new cases and 1.76 million deaths in 2018; equivalent to 11.6% of the global cancer burden.1,2 This incidence is expected ...

European Oncology & Haematology. 2019;15(2):86–8

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Already have an Account?

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Conference Coverage

Learning Activities

Journals

Central Nervous System as a Sanctuary for Advanced Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer

Conference Coverage

Learning Activities

Journals

Central Nervous System as a Sanctuary for Advanced Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer

A Review of Treatment in Non-small-cell Lung Cancer

Abstract

Overview

Article

This Content is for
Members Only

Further Resources

1. Get Permission

2. Share This

Central Nervous System as a Sanctuary for Advanced Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer

Foreword - touchREVIEWS in Oncology & Haematology, Volume 20, Issue 2, 2024

Mesothelioma and Immunotherapies

Foreword - touchREVIEWS in Oncology & Haematology, Volume 20, Issue 1, 2024

A New Frontier in the Treatment of Epidermal Growth Factor Receptor-mutated Non–Small-Cell Lung Cancer: Amivantamab-vmjw and Chemotherapy

Pafolacianine: A Diagnostic Agent to Identify Lung Cancer Lesions in Adults with Known or Suspected Lung Cancer

Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Patients with Non-small Cell Lung Cancer of Squamous Histology: Focus on Afatinib

MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances

Radiation-induced Esophagitis in Lung Cancer—A Common Problem with Limited Therapeutic Options

Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy

ALK Inhibitors in ALK-positive NSCLC with Central Nervous System Metastases

Targeting Tyrosine-protein Kinase Receptor (MET) Gene Alterations in Non-small Cell Lung Cancer – The Efficacy and Safety of Tepotinib + Gefitinib in the INSIGHT Study

Latest articles videos and clinical updates - straight to your inbox

Connect With Us

Useful Links

In Partnership With

Specialities

Sign Up for Free Access to the Latest Clinical Updates in Your Specialty!

Conference Coverage

Learning Activities

Journals

Trending Topic

Connect With Us:

A Review of Treatment in Non-small-cell Lung Cancer

Abstract

Overview

Article

This Content is forMembers Only

Further Resources

1. Get Permission

2. Share This

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Register now for FREE Access

Sign up with an Email

This Functionality is forMembers Only

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

This Content is for
Members Only

This Functionality is for
Members Only